Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis from the Phase 1a study of ELI-002 7P, showing patients receiving ELI-002 7P at a dose of 4.9mg AMP-peptide had yet to reach the median DFS endpoint as of the May 24 cutoff date.
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics shares are trading lower following the announcement of preliminary disease-free survival analysis from the Phase 1a study of ELI-002 7P. The study showed that patients receiving ELI-002 7P at a dose of 4.9mg AMP-peptide had not yet reached the median DFS endpoint as of the May 24 cutoff date.
June 27, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis from the Phase 1a study of ELI-002 7P, showing patients receiving ELI-002 7P at a dose of 4.9mg AMP-peptide had yet to reach the median DFS endpoint as of the May 24 cutoff date.
The preliminary results from the Phase 1a study of ELI-002 7P indicate that patients have not yet reached the median disease-free survival (DFS) endpoint. This uncertainty in clinical trial outcomes is likely causing investor concern, leading to a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100